<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610801</url>
  </required_header>
  <id_info>
    <org_study_id>LCH-3-082020</org_study_id>
    <nct_id>NCT04610801</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2</brief_title>
  <official_title>A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larkin Community Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferrer Medical Innovations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xlear</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Larkin Community Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Xylitol plus Grapefruit Seed Extract&#xD;
      (Xlear) nasal spray as an adjunct treatment of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risk, all patients giving written informed&#xD;
      consent will undergo a brief screening period to determine eligibility for the study. Once&#xD;
      eligibility is confirmed, patients who meet the eligibility requirements will be randomized&#xD;
      placebo control manner. Patient will be assigned to Xlear (2 puffs per nosetrils, every 3-4&#xD;
      hours a day) or placebo. Patient will be followed for 1 week. Inflammatory markers will be&#xD;
      obtained on Day 4 and repeat COVID-19 RT PCR on Day 7. Follow up will be done on Day 14 for&#xD;
      all patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2020</start_date>
  <completion_date type="Anticipated">August 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Masking to care providers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline reactive to non-reactive on COVID 19 RT PCR in 7 days</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>The COVID 19 RT PCR is the gold standard in detecting presence of COVID-19 in patients. The average time from reactivity to non-reactivity is 14 days,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of time to clinical recovery from baseline within 7 days</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>Change in clinical symptoms including but not limited to agnosmia, ageusia, fever, congestion and other clinical symptoms associated with mild COVID-19 infection.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline nasal spray, 2 puffs per nosetrils, every 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Spray</intervention_name>
    <description>Randomized to placebo and Xlear</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Xlear</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults of ages 18 to 90 years of both sexes&#xD;
&#xD;
          2. With positive SARS-CoV-2 carriage confirmed by nasopharyngeal PCR&#xD;
&#xD;
          3. Signed informed consent&#xD;
&#xD;
          4. 1- Mild symptoms: Minimum respiratory symptoms or asymptomatic plus positive test&#xD;
&#xD;
          5. 2- Moderate symptoms: Respiratory symptoms such as cough, mild shortness of breath&#xD;
             with mild oxygen desaturation(room air SpO2 &lt;92% and &gt;88% or &lt;88% corrected to &gt;92%&#xD;
             with 2lt of oxygen)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with very low viral load (threshold cycle [Ct] &gt; 25 per PCR).&#xD;
&#xD;
          2. Known hypersensitivity to one of the constituents, particularly to xylitol or GSE&#xD;
&#xD;
          3. Under 18 years of age&#xD;
&#xD;
          4. Women of childbearing age who are pregnant, breastfeeding mothers, and intend to&#xD;
             become pregnant during the study period; unwilling/unable to take a pregnancy test.&#xD;
&#xD;
          5. Unable to provide informed consent or decline to consent or unwillingness to adhere to&#xD;
             the Standard of Care protocol.&#xD;
&#xD;
          6. Patients with severe symptoms -Hypoxia (SpO2 &lt;88% not corrected by 2 liter&#xD;
             non-concentrated oxygen) plus severe shortness of breath&#xD;
&#xD;
          7. History of immunodeficiency or are currently receiving immunosuppressive therapy.&#xD;
&#xD;
          8. Have had a planned surgical procedure within the past 12 weeks.&#xD;
&#xD;
          9. Already part of this trial, recruited at a different hospital.&#xD;
&#xD;
         10. Patient unable to perform oro-nasopharyngeal decolonization&#xD;
&#xD;
         11. Patients with acute exacerbation of severe comorbidities like heart disorders Chronic&#xD;
             Obstructive Pulmonary Disease (COPD), Heart Failure New York Heart Association (NYHA)&#xD;
             Class 3 and 4 and/or diseases with severe oxygenation problems&#xD;
&#xD;
         12. Patients on Remdesivir and/or other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Larkin Community Hospital Palm Springs Campus</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAMILLE GO</last_name>
      <phone>786-654-9138</phone>
      <email>ccgo@larkinhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcos Sanchez-Gonzalez</last_name>
      <email>masanchez@larkinhospital.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Larkin Community Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Go, MD</last_name>
      <phone>786-654-9138</phone>
      <email>ccgo@larkinhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcos Sanchez-Gonzalez, MD</last_name>
      <email>masanchez@larkinhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>Camille Celeste Go, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Larkin Community Hospital</investigator_affiliation>
    <investigator_full_name>Gustavo Ferrer, M.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Covid 19</keyword>
  <keyword>Intranasal Spray</keyword>
  <keyword>Therapeutics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

